Stefan Nilsson: Treating Metabolic Disease

04/28/22 • 37 min

In this episode we're joined by Dr Stefan Nilsson, founder and CEO of Lipigon Pharmaceuticals, where he discusses the challenges and opportunities in treating metabolic diseases such as dyslipidemia. We also go on to discuss how Lipigon operates as a virtual biotech, allowing it to remain nimble in its efforts to develop novel therapies against a wide range of diseases.
Lipigon was founded in 2010 based on over 50 years of research in lipid biology at Umea University in Sweden. Lipigon develops novel therapeutics for patients with lipid metabolism disorders, and is currently focusing on orphan drugs for rare diseases. There are currently four active projects in Lipigon’s pipeline, including RNA drugs, a gene therapy treatment and a small molecule program. Prior to founding Lipigon, Dr Nilsson was a researcher at Umea University, where he led a group focusing on metabolic disease and was involved with the Umea Biotech Incubator. In addition to this, Stefan has many years of experience working in the pharmaceutical and biotechnology industries, and currently sits on the board of Omnio.

Previous Episode

Chas Bountra: Innovation at Oxford

Prof Chas Bountra, Pro-Vice Chancellor for Innovation and Professor of Translational Medicine at the University of Oxford, joins us in the second episode of Biotech Frontiers for a discussion on the Oxford innovation ecosystem, with a focus on public-private partnerships and initiatives, and the importance of collaboration. Chas draws on his vast experience across industry and academia to suggest ways in which we can better tackle some of the most challenging healthcare problems, such as anti-microbial resistance and the treatment of dementia.
Prof Chas Bountra is Pro-Vice Chancellor for Innovation and Professor of Translational Medicine at the University of Oxford. He is Director of the Centre for Medicines Discovery in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology. In addition to this, Chas is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes.

Prior to returning to Oxford in 2008, Chas was Vice President and Head of Biology at GlaxoSmithKline, where he was involved in the identification of >40 clinical candidates for many gastro-intestinal, inflammatory and neuro-psychiatric diseases. He was involved in the launch and development of the first treatment for Irritable Bowel Syndrome (Alosetron) and was the first to show that neurokinin NK1 antagonists are anti-emetic in preclinical and clinical studies.

As Director of SGC-Oxford from 2008 to mid 2020, he established a leading research group in human protein structural biology and epigenetics chemical biology, and arguably one of the most successful open innovation, public-private partnerships in the world.
Chas has given over 400 invited lectures and in 2012 he was voted one of the “top innovators in the industry”. In 2014 received the “Rita and John Cornforth Award” from the Royal Society of Chemistry, and in 2018 was awarded an OBE in the New Years Honours List for services to Translational Medical Research.